

NCT02973035 Raw comparison:

Summary:
CHIA has 20 criteria while your personal folder has 22 criteria
Total found criteria: 20/20
Total not Found: 0/20
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Controlled hypertension systolic BP < 150 and      │ Controlled hypertension systolic BP \< 150 and     │
│ diastolic BP < 90 mmHg in persons aged 60 years or │ diastolic BP \< 90 mmHg in persons aged 60 years   │
│ older systolic BP < 140 and diastolic BP < 90 mmHg │ or older systolic BP \< 140 and diastolic BP \< 90 │
│ in persons 40 through 59 years according to the    │ mmHg in persons 40 through 59 years according to   │
│ JNC 8th guideline                                  │ the JNC 8th guideline                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of diastolic dysfunction showing E/E' >   │ Evidence of diastolic dysfunction showing E/E' \>  │
│ 10                                                 │ 10                                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient agrees to the study protocol and the   │ The patient agrees to the study protocol and the   │
│ schedule of clinical and echocardiographic follow- │ schedule of clinical and echocardiographic follow- │
│ up and provides informed written consent as        │ up and provides informed written consent as        │
│ approved by the appropriate Institutional Review   │ approved by the appropriate Institutional Review   │
│ Board/Ethical Committee of the respective clinical │ Board/Ethical Committee of the respective clinical │
│ site                                               │ site                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unwillingness or inability to comply with the      │ Unwillingness or inability to comply with the      │
│ procedures described in this protocol              │ procedures described in this protocol              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Planned cardiac surgery or planned major non-      │ Planned cardiac surgery or planned major non-      │
│ cardiac surgery within the study period            │ cardiac surgery within the study period            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stroke or coronary revascularization in the past 6 │ Stroke or coronary revascularization in the past 6 │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant pulmonary disease           │ Clinically significant pulmonary disease           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated hyperthyroidism or hypothyroidism        │ Untreated hyperthyroidism or hypothyroidism        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A diagnosis of cancer (other than superficial      │ A diagnosis of cancer (other than superficial      │
│ squamous or basal cell skin cancer) in the past 3  │ squamous or basal cell skin cancer) in the past 3  │
│ years or current treatment for the active cancer   │ years or current treatment for the active cancer   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female of child-bearing potential who do not use   │ Female of child-bearing potential who do not use   │
│ adequate contraception and women who are pregnant  │ adequate contraception and women who are pregnant  │
│ or breast-feeding                                  │ or breast-feeding                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any clinically significant abnormality identified  │ Any clinically significant abnormality identified  │
│ at the screening visit physical examination        │ at the screening visit physical examination        │
│ laboratory tests or electrocardiogram which in the │ laboratory tests or electrocardiogram which in the │
│ judgment of the Investigator would preclude safe   │ judgment of the Investigator would preclude safe   │
│ completion of the study                            │ completion of the study                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ LV ejection fraction < 50%                         │ LV ejection fraction \< 50%                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant renal disease manifested by serum      │ Significant renal disease manifested by serum      │
│ creatinine > 2 5 mg/dL                             │ creatinine \> 2 5 mg/dL                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hepatic disease or biliary tract obstruction or    │ Hepatic disease or biliary tract obstruction or    │
│ significant hepatic enzyme elevation (ALT or AST > │ significant hepatic enzyme elevation (ALT or AST   │
│ 3 times upper limit of normal)                     │ \> 3 times upper limit of normal)                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of intolerance to ARB or amlodipine        │ History of intolerance to ARB or amlodipine        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hypertrophic or restrictive cardiomyopathy         │ Hypertrophic or restrictive cardiomyopathy         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Moderate or severe valvular disease                │ Moderate or severe valvular disease                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Constrictive pericarditis                          │ Constrictive pericarditis                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Atrial fibrillation with a heart rate > 120/min    │ Atrial fibrillation with a heart rate \> 120/min   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sitting systolic BP < 100 mmHg                     │ Sitting systolic BP \< 100 mmHg                    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 40 Years │
├───────────────────────────────────┤
│ Must have maximum age of 80 Years │
╘═══════════════════════════════════╛